| URL | https://www.fiercepharma.com/pharma/investment-spr |
| Source | Fierce Pharma |
| Date Published | 12/05/2024 |
| Author Name | Kevin Dunleavy |
| Company/Division name | Eli Lilly |
| Type of work | Manufacturing |
| Year reshoring announced: | 2024 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 4500 |
| City reshored to: | Lebanon |
| State(s) reshored to: | IN |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharma, R&D |